desmosine | 1110-20-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: desmosine
• 英文别名: 4-(4-Amino-4-carboxybutyl)-1-(5-amino-5-carboxypentyl)-3,5-bis(3-amino-3-carboxypropyl)pyridinium；2-amino-6-[4-(4-amino-4-carboxybutyl)-3,5-bis(3-amino-3-carboxypropyl)pyridin-1-ium-1-yl]hexanoic acid
• CAS: 1110-20-9
• 化学式: C₂₄H₄₀N₅O₈
• 分子量: 526.61
• InChiKey: VEVRNHHLCPGNDU-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -10.2
• 重原子数：
  37
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  257
• 氢给体数：
  8
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  4,7,10,13,16,19,22,25-八氧杂二十六烷酸 2,5-二氧代-1-吡咯烷基酯 、 desmosine 以 aq. phosphate buffer 为溶剂， 反应 0.33h， 生成 desmosine
  参考文献：
  名称：

  Electron Transfer and Collision Induced Dissociation of Non-Derivatized and Derivatized Desmosine and Isodesmosine

  摘要：

  电子转移解离（ETD）因其与碰撞诱导解离（CID）的互补性而受到越来越多的关注。电子转移解离可直接定位易变的翻译后修饰，这也是蛋白质组学的主要兴趣所在，ETD 和 CID 之间的异同已被广泛研究。然而，由于 ETD 要求前体离子至少带两个电荷，因此人们对代谢物等小分子的 ETD 和 CID 的差异知之甚少。在这项工作中，研究并比较了去甲肌苷（DES）和异去甲肌苷（IDS）的 ETD 和 CID，这两种异构体由于存在一个吡啶基，质子化后可携带两种电荷。此外，还研究了用丙酸酐和聚乙二醇（PEG）试剂衍生 DES/IDS 对 ETD 和 CID 的影响，因为这是提高灵敏度和方便反相色谱分析的常用策略。观察到未衍生化和衍生化 DES/IDS 的 ETD 和 CID 之间存在明显差异。CID 主要归因于电荷定向碎片，而 ETD 则是由初始质子化位点产生的氢原子及其随后转移到 DES/IDS 的吡啶鎓环上引起的。这些差异反映在产生复杂的 CID 图谱上，主要是损失了小的、无信息的分子（NH3、CO、H2O），而 ETD 图谱较为简单，主要是损失了特征性侧链。这也是 ETD 与 CID 相比在生物样本中定向分析 DES/IDS 时的潜在优势。

  DOI：

  10.1007/s13361-012-0504-x

文献信息

• THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE
  申请人：Shchepinov Mikhail S.

  公开号：US20110082208A1

  公开（公告）日：2011-04-07

  Methods of treatment and substances for treatment of cancer may use or cause the creation of isotopically modified lysine at levels that do not occur naturally.

  治疗癌症的方法和治疗物质可能会使用或导致同位素修饰的赖氨酸的创建，其水平不会自然发生。
• SUBSTITUTED XANTHINE DERIVATIVES
  申请人：Tung Roger D.

  公开号：US20140121226A1

  公开（公告）日：2014-05-01

  This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula: wherein the values of R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are described herein.

  本发明涉及新型的氘代化合物，其为取代黄嘌呤衍生物和其药学上可接受的盐。具体而言，本发明涉及一种新型的取代黄嘌呤衍生物，其为戊酰茶碱代谢产物的氘代衍生物。本发明还提供包含本发明中一种或多种化合物和载体的组合物以及在治疗戊酰茶碱和相关化合物有益的疾病和病症的方法中使用所述的氘代化合物和组合物。本发明的化合物由以下结构式表示：其中R1，R2，R3，R4，R5，Y1和Y2的值如本文所述。
• Therapies for cancer using isotopically substituted lysine
  申请人：Shchepinov Mikhail S.

  公开号：US10029956B2

  公开（公告）日：2018-07-24

  Methods of treatment and substances for treatment of cancer may use or cause the creation of isotopically modified lysine at levels that do not occur naturally.

  治疗癌症的方法和物质可能会使用或导致产生天然不存在的同位素修饰赖氨酸。
• DIAGNOSTIC BIOMARKERS FOR VASCULAR ANEURYSM
  申请人：Ogle Matthew F.

  公开号：US20090186370A1

  公开（公告）日：2009-07-23

  Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.
• ELISA ASSAY KIT, ELISA FOR DETERMINING DESMOSINE LEVELS FROM URINE SAMPLES AND DIAGNOSTIC URINE ASSAYS FOR ANEURYSMS
  申请人：Starcher Barry C.

  公开号：US20130273580A1

  公开（公告）日：2013-10-17

  Improved ELISA assay formats are described that provide for effective measurement of desmosine, an elastin degradation product, in urine samples. The urine samples can be effectively introduced into the assay with little or no sample preparation. The competitive ELISA assay based on high titer polyclonal antibodies is suitable for commercial application. Desirable antibodies can be generated using desmosine bound to a protein or the like using a protein crosslinking agent. The desmosine assay are found to be useful for the diagnosis of aortic aneurysms in which desmosine levels of patients with aortic aneurysms have been found to be significantly elevated relative to a control group.